Mammoth Biosciences

Ultra-small CRISPR, Mammoth impact

Mammoth Biosciences logo featuring a green mammoth silhouette next to the company name in white text, with a faint gray mammoth silhouette in the background.

About the project

A decade after the Nobel Prize-winning discovery of CRISPR genome editing, Mammoth Biosciences utilizes its protein discovery engine to harness a robust pipeline of novel “ultra-small” CRISPR systems, driving the technology’s next-generation development. Particularly well-suited to enable reliable in vivo therapeutic editing, Mammoth’s unique platform stands to transform the continuum of care with the potential to permanently cure genetic disease. Beyond healthcare, the company’s CRISPR technology platform enables applications including decentralized precision diagnostics, agriculture, and more.

For the past two years, HDMZ has been the public relations agency of record for Mammoth Biosciences. In that time HDMZ applied a strategic and proactive earned media relations campaign to facilitate the evolution and diversification of Mammoth’s story. With over 160 earned media placements, industry awards wins and major event participation, the efforts have led to worldwide recognition with the biotech industry and trade/mainstream press.

mammoth.bio

Two awards: Fast Company's "Next Big Things In Tech/2022" and Endpoints News' "Biopharma's Most Promising Startups In 2022" for Mammoth Biosciences.
A person's hands are shown interacting with a tablet. Overlayed text reads: "4x the earned articles as its main competitor."
A desktop, tablet, and smartphone display news articles about biotech, CRISPR technology, and business, featuring headlines and images.
A person holds a tablet displaying a Forbes article titled "Mammoth Biosciences Raises $195 Million, Vaulting Its Crispr Tech To Unicorn Status."
A quote about Nobel Prize winner Jennifer Doudna and Janice Chen, co-founders of Mammoth Biosciences, from a CNBC article.

Designed with purpose. Delivered with impact.